linagliptin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
dipeptidyl aminopeptidase-IV inhibitors 4175 668270-12-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • linagliptin
  • tradjenta
  • BI 1356
  • BI-1356
Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation. Both incretin hormones are involved in the physiological regulation of glucose homeostasis. Incretin hormones are secreted at a low basal level throughout the day and levels rise immediately after meal intake. GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta cells in the presence of normal and elevated blood glucose levels. Furthermore, GLP-1 also reduces glucagon secretion from pancreatic alpha cells, resulting in a reduction in hepatic glucose output.
  • Molecular weight: 472.55
  • Formula: C25H28N8O2
  • CLOGP: 2.19
  • LIPINSKI: 0
  • HAC: 10
  • HDO: 1
  • TPSA: 113.48
  • ALOGS: -3.97
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 16 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.90 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 129 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.90 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PRKDC,TEK 20
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
May 2, 2011 FDA BOEHRINGER INGELHEIM
July 1, 2011 PMDA Nippon Boehringer Ingelheim Co., Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigoid 360.38 15.77 123 24691 8903 90594730
Subarachnoid haemorrhage 337.91 15.77 141 24673 17763 90585870
Cardiospasm 330.47 15.77 92 24722 3354 90600279
Palmoplantar keratoderma 328.87 15.77 92 24722 3415 90600218
Hypoglycaemia 320.29 15.77 213 24601 69635 90533998
Pruritus genital 318.00 15.77 95 24719 4463 90599170
Sleep terror 306.93 15.77 92 24722 4372 90599261
Dermatitis bullous 303.24 15.77 112 24702 10204 90593429
Blood glucose increased 288.92 15.77 226 24588 95020 90508613
Atrial tachycardia 284.33 15.77 93 24721 5897 90597736
Carotid artery occlusion 279.12 15.77 93 24721 6249 90597384
Tension headache 263.73 15.77 93 24721 7416 90596217
Anosmia 239.15 15.77 93 24721 9755 90593878
Immunisation 234.92 15.77 64 24750 2149 90601484
Facial pain 206.45 15.77 91 24723 13091 90590542
Vasculitis 195.45 15.77 104 24710 22589 90581044
Pain of skin 195.24 15.77 93 24721 15989 90587644
Ventricular tachycardia 189.89 15.77 105 24709 24603 90579030
Blindness 172.16 15.77 101 24713 26467 90577166
Transient ischaemic attack 170.17 15.77 120 24694 43056 90560577
Lip swelling 167.89 15.77 114 24700 38496 90565137
Eye pruritus 163.89 15.77 101 24713 28926 90574707
Muscle twitching 162.09 15.77 94 24720 24108 90579525
Diplopia 147.25 15.77 94 24720 28620 90575013
Angioedema 140.82 15.77 127 24687 64749 90538884
Tinnitus 125.65 15.77 100 24714 43002 90560631
Hallucination 125.53 15.77 120 24694 65839 90537794
Pancreatitis 114.26 15.77 117 24697 69709 90533924
Glycosylated haemoglobin increased 105.67 15.77 61 24753 15501 90588132
Disturbance in attention 103.75 15.77 93 24721 47016 90556617
Hyperglycaemia 101.30 15.77 95 24719 50875 90552758
Renal impairment 94.71 15.77 130 24684 105291 90498342
Metabolic acidosis 92.37 15.77 94 24720 55582 90548051
Intentional product misuse 92.05 15.77 118 24696 89486 90514147
Acute kidney injury 91.78 15.77 242 24572 320145 90283488
Dehydration 91.61 15.77 179 24635 194268 90409365
Euglycaemic diabetic ketoacidosis 91.28 15.77 41 24773 6160 90597473
Palpitations 90.38 15.77 146 24668 136582 90467051
Pancreatitis haemorrhagic 89.04 15.77 23 24791 626 90603007
Cognitive disorder 88.54 15.77 102 24712 69305 90534328
Rash papular 88.22 15.77 60 24754 20295 90583338
Dry skin 87.36 15.77 114 24700 87959 90515674
Systemic lupus erythematosus 85.78 15.77 3 24811 361893 90241740
Diabetic ketoacidosis 82.86 15.77 62 24752 24345 90579288
Myocardial infarction 80.97 15.77 121 24693 105851 90497782
Lactic acidosis 76.16 15.77 81 24733 50382 90553251
Heart rate increased 73.83 15.77 120 24694 112782 90490851
Diabetes mellitus inadequate control 73.75 15.77 52 24762 18632 90585001
Arthropathy 72.22 15.77 8 24806 366234 90237399
Infusion related reaction 70.94 15.77 14 24800 416766 90186867
Hyperhidrosis 69.73 15.77 130 24684 136175 90467458
Drug ineffective 69.63 15.77 175 24639 1384123 89219510
Hyperkalaemia 68.99 15.77 87 24727 64877 90538756
Rheumatoid arthritis 68.84 15.77 9 24805 362605 90241028
Cardiac failure 67.05 15.77 113 24701 109383 90494250
Wound 66.95 15.77 4 24810 302976 90300657
Glossodynia 66.12 15.77 6 24808 321773 90281860
Drug intolerance 64.72 15.77 21 24793 447570 90156063
Pemphigus 59.95 15.77 9 24805 326855 90276778
Glomerular filtration rate decreased 59.68 15.77 44 24770 16888 90586745
Chronic kidney disease 57.77 15.77 70 24744 50121 90553512
Therapeutic product effect decreased 57.49 15.77 5 24809 277566 90326067
Renal failure 57.33 15.77 117 24697 130890 90472743
COVID-19 57.14 15.77 136 24678 168707 90434926
Drug hypersensitivity 56.81 15.77 28 24786 463581 90140052
Contraindicated product administered 56.07 15.77 10 24804 320129 90283504
Visual impairment 55.32 15.77 116 24698 132249 90471384
Joint swelling 53.69 15.77 36 24778 503264 90100369
Hyperlactacidaemia 53.51 15.77 25 24789 4111 90599522
Feeling abnormal 52.64 15.77 131 24683 167104 90436529
Pancreatic carcinoma 52.03 15.77 31 24783 8346 90595287
Impaired healing 52.01 15.77 3 24811 234196 90369437
Dizziness 51.62 15.77 306 24508 588978 90014655
Helicobacter infection 50.09 15.77 3 24811 226847 90376786
Tachycardia 48.04 15.77 122 24692 157551 90446082
Amnesia 47.58 15.77 97 24717 108408 90495225
Discomfort 47.11 15.77 9 24805 274326 90329307
Cystostomy 45.89 15.77 9 24805 65 90603568
Blood glucose abnormal 43.57 15.77 29 24785 9463 90594170
Muscular weakness 43.55 15.77 140 24674 206526 90397107
Pancreatitis acute 42.29 15.77 48 24766 32067 90571566
Hepatic enzyme increased 40.93 15.77 24 24790 360712 90242921
Diabetic metabolic decompensation 38.89 15.77 16 24798 1941 90601692
Irritable bowel syndrome 37.37 15.77 6 24808 207442 90396191
Psoriatic arthropathy 36.13 15.77 9 24805 228326 90375307
Chest pain 36.05 15.77 178 24636 319467 90284166
Condition aggravated 35.77 15.77 68 24746 595477 90008156
Swelling 33.77 15.77 39 24775 419019 90184614
Vomiting 32.99 15.77 345 24469 787948 89815685
Back pain 32.53 15.77 172 24642 317003 90286630
Blood creatinine increased 32.49 15.77 80 24734 101306 90502327
Hypoglycaemic encephalopathy 32.21 15.77 9 24805 332 90603301
Sinusitis 32.13 15.77 28 24786 343060 90260573
Neoplasm skin 31.63 15.77 16 24798 3126 90600507
Pain 31.03 15.77 154 24660 996187 89607446
Musculoskeletal stiffness 30.53 15.77 22 24792 296510 90307123
Ketoacidosis 30.38 15.77 19 24795 5576 90598057
Memory impairment 29.90 15.77 120 24694 197124 90406509
Abdominal pain upper 29.85 15.77 174 24640 332500 90271133
Ill-defined disorder 29.81 15.77 7 24807 184884 90418749
Hypersensitivity 28.99 15.77 50 24764 454627 90149006
Lower respiratory tract infection 27.96 15.77 17 24797 250642 90352991
Breast cancer metastatic 27.76 15.77 27 24787 15105 90588528
Injury 27.20 15.77 10 24804 197339 90406294
Contusion 26.70 15.77 18 24796 251198 90352435
Haemorrhoidal haemorrhage 26.22 15.77 17 24797 5306 90598327
Urinary tract infection 26.21 15.77 158 24656 305474 90298159
Azotaemia 26.15 15.77 17 24797 5331 90598302
Tubulointerstitial nephritis 25.41 15.77 33 24781 25310 90578323
Urine calcium/creatinine ratio increased 25.13 15.77 6 24808 117 90603516
Stomatitis 25.02 15.77 23 24791 274675 90328958
Pyelonephritis 24.96 15.77 30 24784 21286 90582347
Infection 24.78 15.77 38 24776 362056 90241577
Mucosal membrane hyperplasia 24.72 15.77 5 24809 43 90603590
Therapy non-responder 24.51 15.77 4 24810 136700 90466933
Wheezing 24.07 15.77 18 24796 238062 90365571
Pruritus 24.03 15.77 240 24574 541285 90062348
Nasopharyngitis 23.96 15.77 47 24767 407057 90196576
Shock 23.61 15.77 34 24780 28744 90574889
Vulvovaginal mycotic infection 23.59 15.77 17 24797 6297 90597336
Malaise 23.31 15.77 254 24560 585732 90017901
Product use in unapproved indication 23.28 15.77 35 24779 336201 90267432
Albuminuria 22.92 15.77 7 24807 354 90603279
Blood glucose decreased 22.70 15.77 30 24784 23399 90580234
Sleep disorder 22.69 15.77 13 24801 198017 90405616
Rhabdomyolysis 22.66 15.77 46 24768 51210 90552423
Insulin-like growth factor decreased 22.01 15.77 7 24807 405 90603228
Blood cholesterol increased 21.98 15.77 15 24799 207997 90395636
Urethral caruncle 21.53 15.77 5 24809 86 90603547
Altered state of consciousness 21.25 15.77 34 24780 31498 90572135
Cyclothymic disorder 21.01 15.77 6 24808 240 90603393
Toxic encephalopathy 20.79 15.77 18 24796 8681 90594952
Dementia 20.77 15.77 29 24785 23832 90579801
Incorrect product administration duration 20.70 15.77 26 24788 19296 90584337
Bite 20.36 15.77 7 24807 517 90603116
Adverse event 19.83 15.77 4 24810 117414 90486219
Hypomagnesaemia 19.51 15.77 35 24779 35553 90568080
Blood urea increased 19.42 15.77 32 24782 30381 90573252
Lethargy 19.36 15.77 49 24765 63090 90540543
Wound infection 19.33 15.77 3 24811 106399 90497234
Parathyroid hyperplasia 19.29 15.77 5 24809 138 90603495
Blood potassium increased 19.23 15.77 26 24788 20723 90582910
Asthma 18.99 15.77 23 24791 242137 90361496
Clostridium test positive 18.95 15.77 14 24800 5387 90598246
Autoimmune myositis 18.87 15.77 6 24808 347 90603286
Liver injury 18.42 15.77 12 24802 170555 90433078
Hypoglycaemic coma 18.40 15.77 11 24803 2979 90600654
Hypophagia 18.01 15.77 34 24780 35903 90567730
Haematuria 17.44 15.77 33 24781 34904 90568729
Facet joint syndrome 17.37 15.77 3 24811 98386 90505247
Lung disorder 16.94 15.77 10 24804 149873 90453760
Intentional product use issue 16.63 15.77 109 24705 216783 90386850
Diarrhoea 16.49 15.77 354 24460 938836 89664797
Arthritis 16.46 15.77 13 24801 167302 90436331
Migraine 16.03 15.77 98 24716 190294 90413339
Musculoskeletal pain 15.99 15.77 14 24800 171237 90432396
Injection site reaction 15.84 15.77 3 24811 92077 90511556
Blood creatine increased 15.82 15.77 14 24800 6953 90596680

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigoid 653.10 14.45 252 26419 11215 42583449
Dermatitis bullous 425.65 14.45 170 26501 8286 42586378
Cardiospasm 232.71 14.45 74 26597 1833 42592831
Palmoplantar keratoderma 216.60 14.45 73 26598 2181 42592483
Pruritus genital 205.33 14.45 73 26598 2566 42592098
Sleep terror 197.98 14.45 73 26598 2853 42591811
Tension headache 194.12 14.45 75 26596 3339 42591325
Blood glucose increased 191.20 14.45 233 26438 73466 42521198
Atrial tachycardia 180.11 14.45 75 26596 4065 42590599
Carotid artery occlusion 179.17 14.45 75 26596 4119 42590545
Facial pain 178.04 14.45 75 26596 4185 42590479
Hypoglycaemia 169.64 14.45 198 26473 59656 42535008
Anosmia 160.87 14.45 74 26597 5102 42589562
Immunisation 154.25 14.45 49 26622 1209 42593455
Glycosylated haemoglobin increased 144.81 14.45 94 26577 12830 42581834
Pancreatitis 137.61 14.45 152 26519 43116 42551548
Pain of skin 127.04 14.45 73 26598 8007 42586657
Subarachnoid haemorrhage 107.83 14.45 82 26589 14390 42580274
Muscle twitching 106.45 14.45 75 26596 11705 42582959
Lip swelling 103.96 14.45 90 26581 18963 42575701
Eye pruritus 103.92 14.45 73 26598 11339 42583325
Pericarditis 101.98 14.45 77 26594 13367 42581297
Drug ineffective 101.48 14.45 149 26522 630048 41964616
Blood mercury abnormal 94.09 14.45 24 26647 258 42594406
Ventricular tachycardia 87.42 14.45 101 26570 30059 42564605
Pericardial disease 83.78 14.45 25 26646 497 42594167
Blindness 78.61 14.45 75 26596 17903 42576761
Rash papular 77.31 14.45 62 26609 11749 42582915
Vasculitis 77.15 14.45 75 26596 18319 42576345
Cardiac failure 76.63 14.45 191 26480 106665 42487999
Pulmonary valve disease 75.62 14.45 22 26649 399 42594265
Diplopia 70.90 14.45 75 26596 20241 42574423
Alopecia 66.95 14.45 87 26584 29189 42565475
Left ventricular dysfunction 64.09 14.45 55 26616 11446 42583218
Physical examination abnormal 60.86 14.45 19 26652 442 42594222
Migraine 60.42 14.45 77 26594 25337 42569327
Palpitations 59.71 14.45 111 26560 50686 42543978
Product use in unapproved indication 58.81 14.45 21 26650 184435 42410229
Hyperglycaemia 58.71 14.45 104 26567 45755 42548909
Electrocardiogram Q wave abnormal 58.11 14.45 19 26652 515 42594149
Low density lipoprotein decreased 57.98 14.45 24 26647 1280 42593384
5-hydroxyindolacetic acid in urine increased 57.07 14.45 15 26656 183 42594481
Diabetic ketoacidosis 55.13 14.45 69 26602 22298 42572366
Cognitive disorder 53.76 14.45 85 26586 34087 42560577
Amnesia 53.66 14.45 77 26594 28360 42566304
Hepatojugular reflux 53.64 14.45 19 26652 660 42594004
Visual impairment 52.92 14.45 96 26575 43017 42551647
Tinnitus 51.18 14.45 76 26595 28862 42565802
Euglycaemic diabetic ketoacidosis 51.04 14.45 36 26635 5624 42589040
Disturbance in attention 50.77 14.45 77 26594 29789 42564875
Transient ischaemic attack 49.09 14.45 81 26590 33658 42561006
Hepatic neoplasm 48.96 14.45 25 26646 2166 42592498
Diastolic dysfunction 48.58 14.45 38 26633 6945 42587719
Cardiac discomfort 48.43 14.45 18 26653 719 42593945
Cerebral infarction 48.30 14.45 77 26594 31092 42563572
Abdominal discomfort 48.21 14.45 129 26542 75126 42519538
Helicobacter gastritis 47.23 14.45 21 26650 1336 42593328
Occult blood 46.74 14.45 19 26652 967 42593697
Hypoglycaemic coma 46.38 14.45 26 26645 2718 42591946
Echocardiogram abnormal 45.31 14.45 20 26651 1250 42593414
Dry skin 45.20 14.45 96 26575 48242 42546422
Dehydration 45.16 14.45 192 26479 141575 42453089
Renal impairment 44.61 14.45 161 26510 110067 42484597
Angioedema 42.81 14.45 87 26584 42390 42552274
Diabetic nephropathy 41.81 14.45 23 26648 2318 42592346
Stenosis 41.31 14.45 22 26649 2079 42592585
Carotid artery stenosis 40.92 14.45 31 26640 5405 42589259
Ventricular hyperkinesia 40.82 14.45 12 26659 226 42594438
Aortic valve incompetence 39.96 14.45 33 26638 6515 42588149
Mitral valve disease 38.97 14.45 19 26652 1491 42593173
Right atrial enlargement 38.57 14.45 12 26659 276 42594388
Hyperkalaemia 38.21 14.45 124 26547 80334 42514330
Off label use 37.15 14.45 241 26430 638094 41956570
Tricuspid valve incompetence 36.96 14.45 40 26631 11073 42583591
Hypochromasia 36.92 14.45 12 26659 319 42594345
Acute kidney injury 36.84 14.45 371 26300 366966 42227698
Pancreatic carcinoma 36.59 14.45 37 26634 9469 42585195
Chronic kidney disease 36.53 14.45 87 26584 47154 42547510
Rales 36.12 14.45 40 26631 11360 42583304
Mean platelet volume increased 36.08 14.45 14 26657 630 42594034
Dyspnoea at rest 35.95 14.45 26 26645 4223 42590441
Drug abuse 34.98 14.45 11 26660 104760 42489904
5-hydroxyindolacetic acid increased 34.38 14.45 9 26662 108 42594556
Mucosal dryness 34.20 14.45 18 26653 1660 42593004
Hypovolaemia 34.17 14.45 39 26632 11446 42583218
Carotid arteriosclerosis 33.82 14.45 20 26651 2312 42592352
Disease progression 32.98 14.45 25 26646 143631 42451033
Mitral valve thickening 32.56 14.45 12 26659 468 42594196
Ureteric haemorrhage 32.47 14.45 10 26661 222 42594442
Bundle branch block left 32.14 14.45 29 26642 6447 42588217
Memory impairment 32.06 14.45 86 26585 50136 42544528
Haematocrit increased 32.05 14.45 20 26651 2547 42592117
Expired product administered 31.91 14.45 24 26647 4139 42590525
Death 30.98 14.45 171 26500 471014 42123650
Mitral valve incompetence 30.15 14.45 44 26627 16445 42578219
Heart rate increased 29.86 14.45 87 26584 53168 42541496
Hallucination 29.47 14.45 91 26580 57416 42537248
Lactic acidosis 29.39 14.45 78 26593 45183 42549481
Ventricular arrhythmia 28.98 14.45 27 26644 6252 42588412
Neoplasm 28.88 14.45 27 26644 6278 42588386
Abdominal pain upper 28.72 14.45 115 26556 82494 42512170
Anaemia macrocytic 28.38 14.45 21 26650 3534 42591130
Left atrial dilatation 28.20 14.45 18 26653 2384 42592280
Blood glucose abnormal 28.16 14.45 28 26643 7025 42587639
Haemoglobin increased 27.19 14.45 24 26647 5182 42589482
Blood iron decreased 26.93 14.45 26 26645 6292 42588372
Systolic dysfunction 26.70 14.45 19 26652 3009 42591655
Left atrial enlargement 26.64 14.45 13 26658 1022 42593642
Left ventricular hypertrophy 26.64 14.45 31 26640 9288 42585376
Left ventricular enlargement 26.17 14.45 12 26659 820 42593844
Depression 26.04 14.45 19 26652 111344 42483320
General physical health deterioration 25.91 14.45 34 26637 151212 42443452
Neutropenia 25.66 14.45 54 26617 199377 42395287
Diabetes mellitus inadequate control 25.19 14.45 39 26632 15351 42579313
Pruritus 24.63 14.45 202 26469 188569 42406095
Completed suicide 24.52 14.45 15 26656 96450 42498214
Blood follicle stimulating hormone increased 24.50 14.45 8 26663 216 42594448
Necrotising oesophagitis 24.41 14.45 12 26659 959 42593705
Hypohidrosis 24.19 14.45 8 26663 225 42594439
Pancreatitis acute 24.01 14.45 60 26611 33504 42561160
Peak expiratory flow rate decreased 23.96 14.45 7 26664 129 42594535
Bronchitis viral 22.86 14.45 8 26663 268 42594396
Febrile neutropenia 22.47 14.45 52 26619 185651 42409013
Product dose omission issue 22.29 14.45 39 26632 154326 42440338
Metabolic acidosis 22.02 14.45 77 26594 51781 42542883
Pericardial haemorrhage 21.80 14.45 18 26653 3551 42591113
Pancytopenia 21.70 14.45 25 26646 117718 42476946
Ventricular hypokinesia 21.54 14.45 24 26647 6860 42587804
Acute lung injury 21.42 14.45 13 26658 1576 42593088
Muscular weakness 21.29 14.45 106 26565 83392 42511272
Poikilocytosis 21.09 14.45 7 26664 199 42594465
Pemphigus 21.02 14.45 14 26657 1992 42592672
Fibrous histiocytoma 20.87 14.45 8 26663 348 42594316
Angiopathy 20.83 14.45 21 26650 5356 42589308
Malaise 20.58 14.45 213 26458 211943 42382721
Feeling abnormal 20.27 14.45 92 26579 69694 42524970
Supraventricular tachycardia 19.69 14.45 31 26640 12377 42582287
Chills 19.57 14.45 18 26653 94048 42500616
Renal tubular acidosis 19.20 14.45 15 26656 2735 42591929
Chest pain 19.10 14.45 151 26520 139379 42455285
Tachycardia 18.88 14.45 118 26553 100969 42493695
Seizure 18.76 14.45 29 26642 120532 42474132
Mucosal inflammation 18.73 14.45 4 26667 49370 42545294
Skin disorder 18.62 14.45 36 26635 16908 42577756
Pulmonary embolism 18.39 14.45 29 26642 119583 42475081
Acute myocardial infarction 17.88 14.45 78 26593 58087 42536577
Hypertensive heart disease 17.86 14.45 14 26657 2566 42592098
Diabetic ketoacidotic hyperglycaemic coma 17.71 14.45 6 26665 182 42594482
Infusion related reaction 17.59 14.45 8 26663 60798 42533866
Drug hypersensitivity 17.36 14.45 22 26649 99367 42495297
Peripheral swelling 17.25 14.45 106 26565 90164 42504500
Coma 17.21 14.45 6 26665 53548 42541116
Glomerular filtration rate decreased 17.07 14.45 34 26637 16317 42578347
Red blood cell count decreased 16.96 14.45 52 26619 32663 42562001
Thrombosis 16.93 14.45 11 26660 68500 42526164
Electrocardiogram T wave inversion 16.88 14.45 13 26658 2321 42592343
Vitamin B12 deficiency 16.86 14.45 18 26653 4904 42589760
Hyperaesthesia teeth 16.70 14.45 8 26663 604 42594060
Marasmus 16.52 14.45 9 26662 890 42593774
Psoriasis 16.40 14.45 5 26666 48599 42546065
Gangrene 16.26 14.45 18 26653 5108 42589556
Toxicity to various agents 16.20 14.45 81 26590 229055 42365609
COVID-19 16.15 14.45 126 26545 115822 42478842
Syncope 16.12 14.45 112 26559 99294 42495370
Intentional product misuse 16.07 14.45 79 26592 61821 42532843
Coeliac disease 16.00 14.45 9 26662 947 42593717
Myocardial infarction 15.78 14.45 132 26539 123877 42470787
Diabetic foot 15.72 14.45 14 26657 3059 42591605
Irregular sleep phase 15.56 14.45 5 26666 128 42594536
Interstitial lung disease 15.54 14.45 93 26578 78369 42516295
Therapy non-responder 15.47 14.45 7 26664 53352 42541312
Multiple organ dysfunction syndrome 15.42 14.45 23 26648 97012 42497652
Neuropsychiatric syndrome 15.38 14.45 5 26666 133 42594531
Amylase increased 15.38 14.45 20 26651 6709 42587955
Cardiomegaly 15.32 14.45 33 26638 16733 42577931
Urine ketone body present 15.27 14.45 10 26661 1384 42593280
Therapeutic product effect decreased 15.21 14.45 3 26668 39147 42555517
Incontinence 15.14 14.45 20 26651 6810 42587854
Multifocal motor neuropathy 15.10 14.45 5 26666 141 42594523
Hepatic function abnormal 14.98 14.45 68 26603 51499 42543165
Blindness transient 14.85 14.45 13 26658 2776 42591888
Blister 14.54 14.45 44 26627 27446 42567218
Bronchial hyperreactivity 14.52 14.45 11 26660 1918 42592746

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigoid 981.07 13.62 356 47660 19351 110521932
Dermatitis bullous 592.98 13.62 239 47777 17290 110523993
Cardiospasm 522.87 13.62 158 47858 4809 110536474
Palmoplantar keratoderma 506.02 13.62 157 47859 5230 110536053
Pruritus genital 488.57 13.62 160 47856 6362 110534921
Sleep terror 474.42 13.62 157 47859 6453 110534830
Atrial tachycardia 435.06 13.62 160 47856 9018 110532265
Carotid artery occlusion 428.62 13.62 160 47856 9405 110531878
Tension headache 427.76 13.62 160 47856 9458 110531825
Hypoglycaemia 421.00 13.62 371 47645 115733 110425550
Subarachnoid haemorrhage 397.64 13.62 213 47803 29489 110511794
Blood glucose increased 396.02 13.62 380 47636 132116 110409167
Anosmia 384.03 13.62 159 47857 12313 110528970
Facial pain 355.56 13.62 160 47856 15179 110526104
Immunisation 355.53 13.62 106 47910 3077 110538206
Pain of skin 314.90 13.62 160 47856 19869 110521414
Muscle twitching 259.93 13.62 162 47854 29773 110511510
Ventricular tachycardia 257.27 13.62 196 47820 49813 110491470
Eye pruritus 251.36 13.62 164 47852 32611 110508672
Vasculitis 247.37 13.62 168 47848 35705 110505578
Blindness 245.32 13.62 168 47848 36191 110505092
Lip swelling 229.08 13.62 184 47832 50483 110490800
Glycosylated haemoglobin increased 210.58 13.62 130 47886 23489 110517794
Diplopia 204.12 13.62 159 47857 41735 110499548
Transient ischaemic attack 201.45 13.62 189 47827 63793 110477490
Tinnitus 168.27 13.62 167 47849 60373 110480910
Drug ineffective 160.54 13.62 259 47757 1520281 109021002
Rash papular 159.28 13.62 116 47900 27523 110513760
Disturbance in attention 154.08 13.62 161 47855 61834 110479449
Pancreatitis 151.81 13.62 195 47821 93338 110447945
Angioedema 151.54 13.62 200 47816 98300 110442983
Cardiac failure 151.30 13.62 283 47733 187343 110353940
Acute kidney injury 147.09 13.62 605 47411 634825 109906458
Hallucination 143.92 13.62 198 47818 101234 110440049
Hyperglycaemia 142.20 13.62 180 47836 84910 110456373
Diabetic ketoacidosis 141.59 13.62 129 47887 41929 110499354
Dehydration 140.50 13.62 348 47668 279163 110262120
Euglycaemic diabetic ketoacidosis 137.93 13.62 77 47939 11546 110529737
Cognitive disorder 135.09 13.62 178 47838 87333 110453950
Dry skin 134.82 13.62 198 47818 107455 110433828
Palpitations 128.16 13.62 240 47776 158972 110382311
Renal impairment 122.75 13.62 260 47756 188185 110353098
Hyperkalaemia 110.89 13.62 206 47810 135590 110405693
Chronic kidney disease 106.81 13.62 148 47868 76143 110465140
Metabolic acidosis 105.95 13.62 170 47846 99574 110441709
Blood mercury abnormal 102.81 13.62 24 47992 258 110541025
Synovitis 101.57 13.62 4 48012 274088 110267195
Infusion related reaction 99.32 13.62 22 47994 381140 110160143
Visual impairment 98.78 13.62 195 47821 134233 110407050
Lactic acidosis 96.95 13.62 157 47859 92654 110448629
Arthropathy 92.31 13.62 9 48007 287513 110253770
Heart rate increased 91.96 13.62 197 47819 143637 110397646
Intentional product misuse 90.75 13.62 187 47829 132717 110408566
Drug hypersensitivity 88.93 13.62 43 47973 454047 110087236
Amnesia 88.68 13.62 162 47854 105246 110436037
Diabetes mellitus inadequate control 88.06 13.62 85 47931 29690 110511593
Systemic lupus erythematosus 87.07 13.62 6 48010 254332 110286951
Pulmonary valve disease 87.06 13.62 22 47994 337 110540946
Myocardial infarction 86.95 13.62 230 47786 191853 110349430
Pericardial disease 84.76 13.62 25 47991 698 110540585
Treatment failure 83.18 13.62 11 48005 277223 110264060
Therapeutic product effect decreased 82.95 13.62 6 48010 244310 110296973
Product use in unapproved indication 82.21 13.62 46 47970 447331 110093952
Rheumatoid arthritis 78.63 13.62 17 47999 299596 110241687
Drug intolerance 75.84 13.62 41 47975 406471 110134812
Pancreatic carcinoma 73.62 13.62 57 47959 14815 110526468
Impaired healing 72.44 13.62 3 48013 196714 110344569
Hyperhidrosis 71.67 13.62 211 47805 187087 110354196
Glossodynia 71.12 13.62 7 48009 221997 110319286
COVID-19 69.32 13.62 249 47767 244811 110296472
Cerebral infarction 68.74 13.62 98 47918 51740 110489543
Pancreatitis haemorrhagic 68.39 13.62 23 47993 993 110540290
Glomerular filtration rate decreased 68.02 13.62 73 47943 28883 110512400
Hypoglycaemic coma 66.59 13.62 37 47979 5496 110535787
Hepatic enzyme increased 66.53 13.62 28 47988 320864 110220419
Wound 66.40 13.62 11 48005 234426 110306857
Physical examination abnormal 64.88 13.62 19 47997 517 110540766
Low density lipoprotein decreased 64.47 13.62 24 47992 1398 110539885
Duodenal ulcer perforation 64.47 13.62 3 48013 177697 110363586
5-hydroxyindolacetic acid in urine increased 62.37 13.62 15 48001 185 110541098
Feeling abnormal 62.05 13.62 196 47820 180515 110360768
Helicobacter infection 60.23 13.62 5 48011 181872 110359411
Renal failure 59.69 13.62 225 47791 226349 110314934
Hepatojugular reflux 58.97 13.62 19 47997 716 110540567
Tachycardia 58.82 13.62 224 47792 226421 110314862
Electrocardiogram Q wave abnormal 58.74 13.62 19 47997 725 110540558
Folliculitis 57.24 13.62 4 48012 167649 110373634
Swelling 55.13 13.62 43 47973 350998 110190285
Muscular weakness 52.92 13.62 231 47785 248237 110293046
Psoriatic arthropathy 51.94 13.62 11 48005 196750 110344533
Left ventricular dysfunction 51.30 13.62 57 47959 23436 110517847
Hyperlactacidaemia 50.53 13.62 36 47980 8250 110533033
Diabetic nephropathy 49.30 13.62 26 47990 3482 110537801
Sinusitis 48.30 13.62 35 47981 296653 110244630
Irritable bowel syndrome 48.10 13.62 7 48009 164208 110377075
Chest pain 47.70 13.62 303 47713 376072 110165211
Memory impairment 47.32 13.62 190 47826 196754 110344529
Cardiac discomfort 46.65 13.62 19 47997 1409 110539874
Ureteric haemorrhage 45.27 13.62 11 48005 142 110541141
Hepatic neoplasm 44.20 13.62 25 47991 3842 110537441
Discomfort 44.06 13.62 19 47997 214688 110326595
Hypersensitivity 44.05 13.62 67 47949 403931 110137352
Joint swelling 44.04 13.62 78 47938 442767 110098516
Depression 43.65 13.62 44 47972 317291 110223992
Diastolic dysfunction 43.61 13.62 39 47977 12365 110528918
Hypovolaemia 42.94 13.62 50 47966 21624 110519659
Contusion 42.82 13.62 24 47992 233337 110307946
Pancreatitis acute 42.53 13.62 86 47930 60188 110481095
Blood glucose abnormal 42.26 13.62 39 47977 12877 110528406
Occult blood 41.86 13.62 19 47997 1837 110539446
Ventricular hyperkinesia 41.61 13.62 12 48004 309 110540974
Aortic valve incompetence 41.56 13.62 36 47980 10945 110530338
Migraine 41.55 13.62 166 47850 171486 110369797
Helicobacter gastritis 41.40 13.62 21 47995 2595 110538688
Stomatitis 41.29 13.62 34 47982 270208 110271075
Contraindicated product administered 40.78 13.62 29 47987 248238 110293045
Cystostomy 40.40 13.62 9 48007 77 110541206
Condition aggravated 40.39 13.62 173 47843 734663 109806620
Ketoacidosis 40.07 13.62 34 47982 10053 110531230
Stenosis 39.21 13.62 22 47994 3329 110537954
Blood iron decreased 39.20 13.62 45 47971 19169 110522114
General physical health deterioration 38.70 13.62 79 47937 425216 110116067
Carotid arteriosclerosis 38.32 13.62 21 47995 3036 110538247
Pruritus 38.15 13.62 403 47613 581157 109960126
Echocardiogram abnormal 38.09 13.62 20 47996 2654 110538629
Pemphigus 38.04 13.62 23 47993 214547 110326736
Left ventricular hypertrophy 37.64 13.62 37 47979 13207 110528076
Therapy non-responder 37.25 13.62 11 48005 157296 110383987
Cardiomegaly 37.05 13.62 54 47962 29076 110512207
Haemoglobin increased 36.68 13.62 31 47985 9116 110532167
Dizziness 36.50 13.62 463 47553 697730 109843553
Hepatic function abnormal 36.45 13.62 103 47913 89192 110452091
Carotid artery stenosis 36.34 13.62 31 47985 9232 110532051
5-hydroxyindolacetic acid increased 36.30 13.62 9 48007 127 110541156
Diabetic metabolic decompensation 36.17 13.62 22 47994 3867 110537416
Back pain 36.04 13.62 280 47736 370716 110170567
Right atrial enlargement 36.00 13.62 12 48004 504 110540779
Psoriasis 34.62 13.62 9 48007 139984 110401299
Haematocrit increased 33.64 13.62 23 47993 4936 110536347
Nasopharyngitis 33.59 13.62 76 47940 394285 110146998
Pain 33.54 13.62 260 47756 954695 109586588
Injury 32.85 13.62 18 47998 177247 110364036
Acute myocardial infarction 32.61 13.62 95 47921 83682 110457601
Hypochromasia 32.22 13.62 12 48004 700 110540583
End stage renal disease 32.07 13.62 43 47973 21430 110519853
Dry mouth 32.00 13.62 24 47992 199924 110341359
Lower respiratory tract infection 31.97 13.62 35 47981 243071 110298212
Completed suicide 31.76 13.62 35 47981 242346 110298937
Infection 31.50 13.62 69 47947 362131 110179152
Abdominal pain upper 31.45 13.62 259 47757 348852 110192431
Tricuspid valve incompetence 31.45 13.62 45 47971 23828 110517455
Mitral valve thickening 31.32 13.62 12 48004 757 110540526
Wheezing 31.14 13.62 39 47977 255191 110286092
Facet joint syndrome 31.14 13.62 3 48013 96825 110444458
Expired product administered 30.93 13.62 27 47989 8293 110532990
Mitral valve disease 30.90 13.62 19 47997 3406 110537877
Left atrial enlargement 30.66 13.62 15 48001 1716 110539567
Neutropenia 30.46 13.62 74 47942 374546 110166737
Sleep disorder 30.33 13.62 25 47991 198619 110342664
Ventricular arrhythmia 30.21 13.62 29 47987 10058 110531225
Left ventricular enlargement 29.87 13.62 12 48004 859 110540424
Dyspnoea at rest 28.87 13.62 26 47990 8320 110532963
Systolic dysfunction 28.82 13.62 20 47996 4395 110536888
Blood creatinine increased 28.81 13.62 156 47860 182733 110358550
Mean platelet volume increased 28.71 13.62 14 48002 1590 110539693
Arthritis 28.28 13.62 19 47997 167567 110373716
Injection site reaction 28.02 13.62 3 48013 89067 110452216
Musculoskeletal pain 27.98 13.62 23 47993 183000 110358283
Left atrial dilatation 27.74 13.62 18 47998 3542 110537741
Interstitial lung disease 27.73 13.62 127 47889 139207 110402076
Bundle branch block left 27.67 13.62 31 47985 12857 110528426
Paraesthesia 27.20 13.62 49 47967 276472 110264811
Mucosal dryness 27.10 13.62 19 47997 4244 110537039
Adverse event 26.89 13.62 7 48009 108802 110432481
Liver injury 26.83 13.62 16 48000 150397 110390886
Drug ineffective for unapproved indication 26.62 13.62 6 48010 102832 110438451
Product dose omission issue 26.60 13.62 63 47953 321719 110219564
Gastrointestinal disorder 26.47 13.62 40 47976 241912 110299371
Inflammation 26.32 13.62 27 47989 193211 110348072
Weight increased 26.07 13.62 94 47922 419550 110121733
Off label use 25.76 13.62 478 47538 1499707 109041576
Chills 25.54 13.62 27 47989 190553 110350730
Diabetic foot 25.45 13.62 18 47998 4077 110537206
Hypoglycaemic encephalopathy 25.06 13.62 10 48006 703 110540580
Gait inability 25.04 13.62 14 48002 136362 110404921
Syncope 24.97 13.62 162 47854 202374 110338909
Rales 24.67 13.62 41 47975 24698 110516585
Musculoskeletal stiffness 24.58 13.62 53 47963 279769 110261514
Neoplasm skin 24.47 13.62 16 48000 3188 110538095
Hypohidrosis 24.42 13.62 8 48008 318 110540965
Neoplasm 24.38 13.62 27 47989 11060 110530223
Malaise 24.25 13.62 418 47598 671401 109869882
Wound infection 24.24 13.62 6 48010 96459 110444824
Injection site erythema 23.39 13.62 6 48010 94170 110447113
Obesity 23.30 13.62 10 48006 113341 110427942
Hypoaesthesia 23.29 13.62 65 47951 314158 110227125
Clostridium test positive 23.05 13.62 26 47990 10867 110530416
Pain in extremity 23.01 13.62 121 47895 486997 110054286
Azotaemia 22.94 13.62 25 47991 10060 110531223
Necrotising oesophagitis 22.89 13.62 12 48004 1588 110539695
Mitral valve incompetence 22.85 13.62 47 47969 33282 110508001
Loss of personal independence in daily activities 22.75 13.62 19 47997 150001 110391282
Blood follicle stimulating hormone increased 22.60 13.62 8 48008 403 110540880
Vomiting 22.37 13.62 535 47481 910140 109631143
Altered state of consciousness 22.09 13.62 65 47951 57561 110483722
Anaemia macrocytic 21.88 13.62 21 47995 7282 110534001
Mobility decreased 21.66 13.62 44 47972 237378 110303905
Peripheral venous disease 21.59 13.62 5 48011 84112 110457171
Pericardial haemorrhage 21.58 13.62 18 47998 5199 110536084
Diabetic ketoacidotic hyperglycaemic coma 21.52 13.62 7 48009 272 110541011
Lipase increased 21.44 13.62 33 47983 18639 110522644
Mucosal membrane hyperplasia 21.40 13.62 5 48011 54 110541229
Renal disorder 21.10 13.62 58 47958 49421 110491862
Urine calcium/creatinine ratio increased 21.01 13.62 6 48010 149 110541134
Pulmonary fibrosis 20.97 13.62 9 48007 102033 110439250
Mucosal inflammation 20.54 13.62 8 48008 96133 110445150
Penile oedema 20.53 13.62 7 48009 315 110540968
Angiopathy 20.48 13.62 22 47994 8708 110532575
Haemodynamic instability 20.28 13.62 36 47980 22852 110518431
Urethral caruncle 20.14 13.62 5 48011 71 110541212
Diabetes mellitus 20.08 13.62 91 47925 99290 110441993
Suicidal ideation 19.77 13.62 8 48008 93929 110447354
Road traffic accident 19.76 13.62 11 48005 107387 110433896
Coronary artery stenosis 19.71 13.62 27 47989 13731 110527552
Urine ketone body present 19.60 13.62 15 48001 3831 110537452
Marasmus 19.51 13.62 11 48005 1680 110539603
Peripheral arterial occlusive disease 19.38 13.62 22 47994 9258 110532025
Ventricular hypokinesia 19.16 13.62 24 47992 11190 110530093
Vulvovaginal mycotic infection 19.09 13.62 17 47999 5360 110535923
Poikilocytosis 19.02 13.62 7 48009 395 110540888
Pyelonephritis 18.98 13.62 37 47979 25213 110516070
Respiratory disorder 18.81 13.62 4 48012 71378 110469905
Autoimmune disorder 18.69 13.62 3 48013 65480 110475803
Melaena 18.68 13.62 69 47947 68688 110472595
Supraventricular tachycardia 18.61 13.62 36 47980 24386 110516897
Amylase increased 18.59 13.62 25 47991 12494 110528789
Peak expiratory flow rate decreased 18.47 13.62 8 48008 692 110540591
Erythema multiforme 18.46 13.62 33 47983 21064 110520219
Asthma 18.38 13.62 52 47964 250239 110291044
Pericarditis 18.36 13.62 160 47856 218954 110322329
Cardiac failure chronic 18.14 13.62 26 47990 13785 110527498
Glomerulonephritis membranous 17.78 13.62 11 48005 1992 110539291
Acute lung injury 17.64 13.62 13 48003 3138 110538145
Dementia 17.55 13.62 41 47975 31632 110509651
Fibrous histiocytoma 17.08 13.62 8 48008 831 110540452
Multifocal motor neuropathy 17.08 13.62 5 48011 136 110541147
Injection site pain 17.07 13.62 32 47984 177890 110363393
Blood cholesterol increased 17.06 13.62 34 47982 184751 110356532
Renal tubular acidosis 16.92 13.62 15 48001 4700 110536583
Intentional product use issue 16.78 13.62 173 47843 247733 110293550
Coma 16.59 13.62 16 48000 117853 110423430
Sputum discoloured 16.39 13.62 37 47979 27908 110513375
Electrocardiogram T wave inversion 16.39 13.62 16 48000 5664 110535619
Vitamin B12 deficiency 16.35 13.62 21 47995 10034 110531249
Irregular sleep phase 16.27 13.62 5 48011 161 110541122
Flushing 16.21 13.62 13 48003 104723 110436560
Insulin-like growth factor decreased 16.15 13.62 7 48009 606 110540677
Therapeutic product effect incomplete 16.06 13.62 47 47969 223758 110317525
Bite 16.02 13.62 7 48009 618 110540665
Nail disorder 15.78 13.62 3 48013 57932 110483351
Parathyroid hyperplasia 15.76 13.62 5 48011 179 110541104
Confusional state 15.75 13.62 129 47887 468551 110072732
Hypercholesterolaemia 15.73 13.62 10 48006 90827 110450456
Albuminuria 15.66 13.62 8 48008 1003 110540280
Haematuria 15.29 13.62 74 47942 82931 110458352
Hypertensive heart disease 15.27 13.62 14 48002 4582 110536701
Drug abuse 15.24 13.62 34 47982 177377 110363906
Type 2 diabetes mellitus 15.20 13.62 34 47982 177198 110364085
Lung disorder 15.07 13.62 35 47981 180012 110361271
Diarrhoea 15.06 13.62 621 47395 1138884 109402399
Haemorrhoidal haemorrhage 14.92 13.62 18 47998 8075 110533208
Jaundice 14.90 13.62 58 47958 59178 110482105
Neuropsychiatric syndrome 14.82 13.62 5 48011 218 110541065
Urinary tract infection 14.78 13.62 211 47805 326071 110215212
Shock 14.74 13.62 54 47962 53534 110487749
Epidermolysis 14.51 13.62 8 48008 1170 110540113
Ill-defined disorder 14.36 13.62 29 47987 156824 110384459
Insomnia 14.32 13.62 228 47788 360362 110180921
Disease progression 14.27 13.62 56 47960 243978 110297305
Cardiac failure acute 14.26 13.62 32 47984 24046 110517237
Femoral neck fracture 14.13 13.62 22 47994 12545 110528738
Throat irritation 14.11 13.62 3 48013 53549 110487734
Osteoarthritis 14.11 13.62 37 47979 182586 110358697
Rhabdomyolysis 14.04 13.62 95 47921 120306 110420977
Aplasia pure red cell 14.03 13.62 19 47997 9559 110531724
Pharyngeal perforation 14.00 13.62 3 48013 21 110541262
Intraductal papillary mucinous neoplasm 13.90 13.62 7 48009 852 110540431
Red blood cell count decreased 13.79 13.62 61 47955 65862 110475421
Joint stiffness 13.71 13.62 6 48010 67237 110474046

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BD11 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD19 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD27 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BH05 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Dipeptidyl peptidase 4 (DPP-4) inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006728 Hormones
MeSH PA D007004 Hypoglycemic Agents
MeSH PA D011480 Protease Inhibitors
MeSH PA D054795 Incretins
MeSH PA D054873 Dipeptidyl-Peptidase IV Inhibitors
FDA MoA N0000175912 Dipeptidyl Peptidase 4 Inhibitors
FDA EPC N0000175913 Dipeptidyl Peptidase 4 Inhibitor
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:68612 EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor

Related Drugs by ATC class:

A10BD Combinations of oral blood glucose lowering drugs 19 drugs
acarbosealogliptincanagliflozindapagliflozinempagliflozinertugliflozinevogliptingemigliptinglimepiridelobeglitazonemetforminphenformin show all 19 →
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors 9 drugs
alogliptinevogliptingemigliptinrosuvastatinsaxagliptinsimvastatinsitagliptinteneligliptinvildagliptin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Pancreatitis contraindication 75694006 DOID:4989
Hypoglycemic disorder contraindication 237630007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.16 Basic
pKa2 6.13 Basic
pKa3 3.79 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 10034877 Aug. 5, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN WITHOUT DOSE ADJUSTMENT
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 9486526 Aug. 5, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 11911388 April 10, 2030 LINAGLIPTIN (5 MG DAILY DOSE) AND METFORMIN (WITH OR WITHOUT INSULIN) FOR TREATING TYPE 2 DIABETES PATIENTS WITH RENAL IMPAIRMENT AND INSUFFICIENT GLYCEMIC CONTROL DESPITE PREVIOUS TREATMENT WITH METFORMIN ALONE OR IN COMBINATION WITH INSULIN
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 11911388 April 10, 2030 LINAGLIPTIN (5 MG DAILY DOSE) AND METFORMIN (WITH OR WITHOUT INSULIN) FOR TREATING TYPE 2 DIABETES PATIENTS WITH RENAL IMPAIRMENT AND INSUFFICIENT GLYCEMIC CONTROL DESPITE PREVIOUS TREATMENT WITH METFORMIN ALONE OR IN COMBINATION WITH INSULIN
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 11911388 April 10, 2030 LINAGLIPTIN (5 MG DAILY DOSE) AND METFORMIN (WITH OR WITHOUT INSULIN) FOR TREATING TYPE 2 DIABETES PATIENTS WITH RENAL IMPAIRMENT AND INSUFFICIENT GLYCEMIC CONTROL DESPITE PREVIOUS TREATMENT WITH METFORMIN ALONE OR IN COMBINATION WITH INSULIN
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 11911388 April 10, 2030 LINAGLIPTIN (5 MG DAILY DOSE) AND METFORMIN (WITH OR WITHOUT INSULIN) FOR TREATING TYPE 2 DIABETES PATIENTS WITH RENAL IMPAIRMENT AND INSUFFICIENT GLYCEMIC CONTROL DESPITE PREVIOUS TREATMENT WITH METFORMIN ALONE OR IN COMBINATION WITH INSULIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 11911388 April 10, 2030 LINAGLIPTIN (5 MG DAILY DOSE) AND METFORMIN (WITH OR WITHOUT INSULIN) FOR TREATING TYPE 2 DIABETES PATIENTS WITH RENAL IMPAIRMENT AND INSUFFICIENT GLYCEMIC CONTROL DESPITE PREVIOUS TREATMENT WITH METFORMIN ALONE OR IN COMBINATION WITH INSULIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 11911388 April 10, 2030 LINAGLIPTIN (5 MG DAILY DOSE) AND METFORMIN (WITH OR WITHOUT INSULIN) FOR TREATING TYPE 2 DIABETES PATIENTS WITH RENAL IMPAIRMENT AND INSUFFICIENT GLYCEMIC CONTROL DESPITE PREVIOUS TREATMENT WITH METFORMIN ALONE OR IN COMBINATION WITH INSULIN
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 8853156 March 5, 2031 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11564886 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11564886 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11564886 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
5MG TRADJENTA BOEHRINGER INGELHEIM N201280 May 2, 2011 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Dipeptidyl peptidase 4 Enzyme INHIBITOR IC50 10 CHEMBL CHEMBL
Prolyl endopeptidase FAP Enzyme IC50 7.05 CHEMBL
Dipeptidyl peptidase 8 Enzyme IC50 4.40 CHEMBL
Dipeptidyl peptidase 9 Enzyme IC50 4 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR IC50 6.53 CHEMBL
Dipeptidyl peptidase 4 Enzyme IC50 9.92 CHEMBL
Prolyl endopeptidase FAP Enzyme IC50 6.43 CHEMBL
Dipeptidyl peptidase IV Enzyme IC50 5 CHEMBL

External reference:

IDSource
4030725 VUID
N0000182735 NUI
D09566 KEGG_DRUG
4030725 VANDF
C2746078 UMLSCUI
CHEBI:68610 CHEBI
356 PDB_CHEM_ID
CHEMBL237500 ChEMBL_ID
D000069476 MESH_DESCRIPTOR_UI
DB08882 DRUGBANK_ID
6318 IUPHAR_LIGAND_ID
9039 INN_ID
3X29ZEJ4R2 UNII
10096344 PUBCHEM_CID
1100699 RXNORM
181237 MMSL
27861 MMSL
d07767 MMSL
013732 NDDF
702798009 SNOMEDCT_US
703667006 SNOMEDCT_US
3X29ZEJ4R2 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tradjenta HUMAN PRESCRIPTION DRUG LABEL 1 0597-0140 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Jentadueto HUMAN PRESCRIPTION DRUG LABEL 2 0597-0146 TABLET, FILM COATED 2.50 mg ORAL NDA 33 sections
Jentadueto HUMAN PRESCRIPTION DRUG LABEL 2 0597-0147 TABLET, FILM COATED 2.50 mg ORAL NDA 33 sections
Jentadueto HUMAN PRESCRIPTION DRUG LABEL 2 0597-0148 TABLET, FILM COATED 2.50 mg ORAL NDA 33 sections
Glyxambi HUMAN PRESCRIPTION DRUG LABEL 2 0597-0164 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Glyxambi HUMAN PRESCRIPTION DRUG LABEL 2 0597-0164 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Glyxambi HUMAN PRESCRIPTION DRUG LABEL 2 0597-0182 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Glyxambi HUMAN PRESCRIPTION DRUG LABEL 2 0597-0182 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Jentadueto XR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0270 TABLET, FILM COATED, EXTENDED RELEASE 2.50 mg ORAL NDA 33 sections
Jentadueto XR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0275 TABLET, FILM COATED, EXTENDED RELEASE 5 mg ORAL NDA 33 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0380 TABLET, EXTENDED RELEASE 5 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0380 TABLET, EXTENDED RELEASE 5 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0385 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0385 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0390 TABLET, EXTENDED RELEASE 5 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0390 TABLET, EXTENDED RELEASE 5 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0395 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0395 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 34 sections
linagliptin HUMAN PRESCRIPTION DRUG LABEL 1 48792-7865 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections
Tradjenta HUMAN PRESCRIPTION DRUG LABEL 1 50090-4383 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Jentadueto HUMAN PRESCRIPTION DRUG LABEL 2 54868-6461 TABLET, FILM COATED 2.50 mg ORAL NDA 28 sections
Tradjenta HUMAN PRESCRIPTION DRUG LABEL 1 55154-0410 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Linagliptin and metformin hydrochloride Human Prescription Drug Label 2 72205-407 TABLET, FILM COATED 2.50 mg ORAL ANDA 26 sections
Linagliptin and metformin hydrochloride Human Prescription Drug Label 2 72205-408 TABLET, FILM COATED 2.50 mg ORAL ANDA 26 sections
Linagliptin and metformin hydrochloride Human Prescription Drug Label 2 72205-409 TABLET, FILM COATED 2.50 mg ORAL ANDA 26 sections